Good morning :)
Place Order
Add to Watchlist

Hikal Ltd

HIKAL

Hikal Ltd

HIKAL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,565 cr, stock is ranked 794
Moderate RiskStock is 2.67x as volatile as Nifty
370.302.72% (-10.35)
370.302.72% (-10.35)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,565 cr, stock is ranked 794
Moderate RiskStock is 2.67x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,565 cr, stock is ranked 794
Moderate RiskStock is 2.67x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
67.433.840.32%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.296.550.51%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients and contract research activities. The Company offers pharmaceuticals and agrochemicals.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 2.34%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.73% to 0.47%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -7.55%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue927.491,017.381,300.551,591.871,510.961,725.421,947.612,028.441,787.051,805.50
Raw Materialssubtract447.77494.83715.32868.80781.90906.711,032.211,121.59805.151,528.77
Power & Fuel Costsubtract83.7085.63108.41132.04129.99147.83175.46186.91170.16
Employee Costsubtract109.65116.69128.06135.69156.57164.32203.38222.44246.53
Selling & Administrative Expensessubtract41.6343.7445.9052.5055.5764.0595.21107.96113.59
Operating & Other expensessubtract62.0678.8056.67102.46125.48114.6495.91127.06182.14
Depreciation/Amortizationsubtract67.2869.1485.5992.8882.4685.2595.67109.01117.61121.64
Interest & Other Itemssubtract62.2148.2749.1258.4352.4236.2031.2248.1056.3762.42
Taxes & Other Itemssubtract11.9912.5434.2746.0142.1473.2858.0626.9925.9024.96
EPS3.345.496.268.366.8510.8013.026.365.645.49
DPS0.670.800.801.201.202.001.601.201.201.20
Payout ratio0.200.150.130.140.180.190.120.190.210.22

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 7PDF
FY 2022

Annual report

PDF

Investor Presentation

May 28PDF
Feb 14PDF
Oct 26PDF
Aug 5PDF
FY 2023

Annual report

PDF

Investor Presentation

May 29PDF
Feb 2PDF
Nov 9PDF
Aug 10PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 8PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Hikal Ltd65.603.840.32%
Sun Pharmaceutical Industries Ltd45.326.470.75%
Cipla Ltd31.054.770.82%
Mankind Pharma Ltd57.2011.43—

Price Comparison

Compare HIKAL with any stock or ETF
Compare HIKAL with any stock or ETF
HIKAL
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.85%3.22%0.36%6.78%20.79%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep4.56%4.81%6.13%6.55%6.67%6.78%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Hikal Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Tata Small Cap Fund-Direct Plan-Growth

Growth
2.6179%1.32%-0.08%33/54 (0)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth

Growth
0.2979%0.28%0.28%47/48 (-2)
Kotak Healthcare Fund - Growth - Direct Plan

Growth
0.1666%1.95%1.95%21/34 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

HIKAL has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.24 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 4, 2024

Final
Final | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Sep 4, 2024

Cash Dividend

Ex DateEx DateFeb 20, 2024

Interim
Interim | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Feb 20, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateFeb 14, 2023

Interim
Interim | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Feb 14, 2023

Cash Dividend

Ex DateEx DateSep 14, 2022

Final
Final | Div/Share: ₹0.40

Dividend/Share

₹0.40

Ex DateEx Date

Sep 14, 2022

News & Opinions
Corporate
Hikal AGM scheduled

Hikal announced that the Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Hikal consolidated net profit declines 26.09% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Hikal consolidated net profit declines 26.09% in the June 2024 quarter

Net profit of Hikal declined 26.09% to Rs 5.10 crore in the quarter ended June 2024 as against Rs 6.90 crore during the previous quarter ended June 2023. Sales rose 4.58% to Rs 403.80 crore in the quarter ended June 2024 as against Rs 386.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales403.80386.10 5 OPM %14.3613.03 - PBDT38.7037.40 3 PBT6.909.70 -29 NP5.106.90 -26 Powered by Capital Market - Live

3 months agoCapital Market - Live

Sonata Software Ltd leads losers in ‘A’ group

3 months agoBusiness Standard
Corporate
Hikal to hold board meeting

Hikal will hold a meeting of the Board of Directors of the Company on 1 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

MRPL, Hikal among top picks by Jigar S Patel of Anand Rathi for July 15

3 months agoBusiness Standard
Bharat Forge MD Baba Kalyani Ousted From Hikal's Board | CNBC TV18
10 months agoCNBC-TV18
Key Stocks In Focus: Cipla, Oberoi Realty, SBI Card, ESAF SFB, Zen Tech, RITES, Hikal | CNBC TV18
11 months agoCNBC-TV18

Titan, Britannia, Tata Steel — Buy, Sell Or Hold? AskBQ

1 year agoBloomberg Quint

Kalyani Group firms deny being party to any family pact

1 year agoThe Hindu Businessline